Men, age 18 years or older, who meet the following criteria:

• Patients with metastatic castration-resistant prostate cancer (mCRPC), a cancer that has spread (metastasized) beyond the prostate gland and for which hormone therapy is no longer effective.

At enrollment, patients must fit into one of the following 5 categories:

• Have not yet started approved therapies for CRPC ie: Abiraterone/Enzalutamide/Apalutamide/Docetaxel), Or
• Have received Abi/Enza/Apa for mCRPC and cancer is responding or stable, Or
• Patients with PSA progression while on Abi/Enza/Apa are eligible as long as they are asymptomatic AND there is no plan to start chemotherapy within 6 months, Or
• Patients treated with Docetaxel as first line therapy for mCRPC who are asymptomatic without ANY evidence of progression, Or
• Patients may have progressed following Docetaxel first line and are now receiving treatment with Abi/Enza/Apa. These patients must be responding or stable (PSA values must be stable or declining after starting Abi/Enza/Apa treatment) and have an expected life expectancy of more than 1 year.

Patients must be able to travel to one of the study-designated exercise facilities up to three days per week for four weeks during cycle 0, two days per week for cycles 1-8 (32 weeks) and once per week for cycles 9-11 (12 weeks). In addition, patients must be able to attend exercise testing visits as defined in the study.

Receive medical clearance to undergo and pass a symptom-limited cardiopulmonary exercise test (CPET) and vigorous aerobic and resistance exercise training.
Receive approval after review of patient’s bone scan.

• Disease progression while on treatment with abiraterone, enzalutamide, or a combination.
• Small cell neuroendocrine tumors or pure small cell carcinoma of the prostate.
• Brain metastases.
• Patients receiving experimental treatment with non-approved drugs at the time of enrollment must undergo a 28-day washout between last dose and screening CPET.
• Serious event associated with heart disease within the last 12 months.
• Patients with a currently active second cancer other than non-melanoma skin cancer.
• Serious or non-healing wound, bone fracture, or moderate-to-severe bone pain.
• Men already participating in vigorous aerobic exercise for more than 60 minutes per week or resistance exercise two or more days per week.